Given the supportive role of senescent cells for tumor cell development, via a profound secretory phenotype with pro-inflammatory characteristics [52] contributing to therapy resistance [53], it should be kept in mind that tumor cells which survived Plk1 inhibitor treatment could contribute to a more aggressive cancer development. This evidence concerns the gene PLK1 and neoplasm.